Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort

• Published in: Pharmacology research & perspectives 2021-05, Vol.9 (3), p.e00781-n/a
• Main Authors: Lemelin, Maxim, Boukhris, Takoua, Zhao, Jin‐Ping, Sheehy, Odile, Bérard, Anick
• Format: Article
• Language: English
• Subjects: Adolescent; Adrenergic Uptake Inhibitors - therapeutic use; Adult; Age; Amphetamines; Atomoxetine Hydrochloride - therapeutic use; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention Deficit Disorder with Hyperactivity - epidemiology; Attention deficit hyperactivity disorder; attention deficit/hyperactivity disorders (ADHD); Birth defects; Central Nervous System Stimulants - therapeutic use; Cohort Studies; Congenital diseases; dosage; Drug dosages; Drug Utilization - statistics & numerical data; Female; Humans; Hyperactivity; Maternal-Fetal Exchange; Menstruation; methylphenidate; non‐stimulants; Original; Pharmacology; Pregnancy; prenatal exposure; Prescription drugs; Prevalence; Quebec - epidemiology; Quebec Pregnancy Cohort; Stimulants; Trends; Womens health; Young Adult
• ISSN: 2052-1707; 2052-1707
• DOI: 10.1002/prp2.781

Aims The use of attention deficit/hyperactivity disorder (ADHD) medications has grown over the past decade among pregnant women, but these treatments are not without risk. Updated prevalence of ADHD medication use and whether prescribed dosages follow guidelines are needed. The aim of this study is to describe the prevalence of ADHD medication use among pregnant women—dosages and switches—and identify determinants of ADHD medication use. Method A population‐based longitudinal cohort study within the Quebec Pregnancy/Children Cohort (QPC). Women aged 15–45 years old covered by the RAMQ prescription drug plan for at least 12 months before and during pregnancy from 1998 to 2015. ADHD medication exposure was assessed before and during pregnancy. We estimated odds ratios (ORs) for determinants of ADHD medication use during pregnancy with generalized estimating equations. Results Among 428,505 included pregnant women, 1,130 (0.26%) used ADHD medication. A 14‐fold increase in the prevalence of ADHD medication use in pregnant women was observed, from 1998 (0.08%) to 2015 (1.2%). Methylphenidate was the most prevalent medication at 70.1%. ADHD medication fillings were at optimal dosage 91.8% of the time based on guidelines and 18.1% of women switched to another ADHD medication class during gestation. Main determinants of ADHD medication use during pregnancy were psychiatric disorders (aOR 2.19; 95% confidence interval [CI] 1.57, 2.96), mood and anxiety disorders (aOR 1.74; 95% CI 1.32, 2.24), and calendar year. Conclusions The number of pregnancies exposed to ADHD medications has increased similarly to the increase reported in other countries between 1998 and 2015. In addition to the current literature, the use of ADHD medications during pregnancy is consistent with Canadian guidelines recommendations on dosage.